INS and metabolic disease: GLP-1 acts on the pancreas to control insulin secretion and GLP-1-based therapies are now FDA (Food and Drug Administration)-approved for the treatment of T2D [94,95], however, patients with multiple metabolic diseases are likely to have a complicated EEC response to the available therapeutics.